FDA Approves VALPROATE SODIUM — Fresenius Kabi USA, LLC

# FDA Approves Fresenius Kabi's Intravenous Valproate Sodium Formulation Fresenius Kabi USA, LLC received FDA approval for its intravenous valproate sodium formulation (ANDA076539), expanding the company's presence in the anticonvulsant market and providing an alternative delivery route for patients who cannot tolerate oral medications. The approval of the injectable variant strengthens Fresenius Kabi's portfolio in hospital and acute care settings, where IV administration is critical for treating seizure disorders and mood stabilization.